<< Back To Search

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study is checking if a medicine called Isatuximab can help people's kidneys work better if they have a problem called MGRS. Isatuximab is already allowed by the FDA for people with another condition, but not for MGRS yet. This means they are still testing it to make sure it works for MGRS too.
*Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?